2022
DOI: 10.3389/fbioe.2022.793945
|View full text |Cite
|
Sign up to set email alerts
|

Electronic Bone Growth Stimulators for Augmentation of Osteogenesis in In Vitro and In Vivo Models: A Narrative Review of Electrical Stimulation Mechanisms and Device Specifications

Abstract: Since the piezoelectric quality of bone was discovered in 1957, scientists have applied exogenous electrical stimulation for the purpose of healing. Despite the efforts made over the past 60 years, electronic bone growth stimulators are not in common clinical use. Reasons for this include high cost and lack of faith in the efficacy of bone growth stimulators on behalf of clinicians. The purpose of this narrative review is to examine the preclinical body of literature supporting electrical stimulation and its e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
24
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1
1

Relationship

3
4

Authors

Journals

citations
Cited by 18 publications
(28 citation statements)
references
References 74 publications
0
24
0
Order By: Relevance
“…These studies applied a wide range of stimulation currents and were successful in inducing osteogenesis within a range of 20–100 μA, and lower stimulation currents (13 μA) were not successful ( Nerubay et al, 1986 ; Chakkalakal et al, 1990 ; Toth et al, 2000 ). These results are problematic for translation into humans, however, because these studies used custom-built stimulators and did not report cathode material, lead geometry, or measures of current density in all cases ( Nicksic et al, 2022 ). Direct current electrical stimulation remains largely unstudied in humans as it is impractical, requiring operations for lead placement and removal and presenting an unacceptable infection risk ( Jorgensen, 1977 ).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…These studies applied a wide range of stimulation currents and were successful in inducing osteogenesis within a range of 20–100 μA, and lower stimulation currents (13 μA) were not successful ( Nerubay et al, 1986 ; Chakkalakal et al, 1990 ; Toth et al, 2000 ). These results are problematic for translation into humans, however, because these studies used custom-built stimulators and did not report cathode material, lead geometry, or measures of current density in all cases ( Nicksic et al, 2022 ). Direct current electrical stimulation remains largely unstudied in humans as it is impractical, requiring operations for lead placement and removal and presenting an unacceptable infection risk ( Jorgensen, 1977 ).…”
Section: Discussionmentioning
confidence: 99%
“…For example, the thickness of tissue planes (fat, muscle, and bone) and their relative difference in resistivity, as well as even small changes in the placement of the PEMF device with relationship to the fracture, dramatically change the intensity of the electrical field at the fracture site ( Lunt, 1985 ). By contrast to in vitro and small animal studies, large animal studies have largely been unsuccessful in inducing osteogenesis with PEMF therapy ( Nicksic et al, 2022 ). Studies to date have included a range of indications in both canine and sheep models ( Miller et al, 1984 ; Law et al, 1985 ), but the single study that was able to demonstrate benefit for PEMF therapy applied 0.2 mT, 1.5 Hz stimulation to a canine mid-diaphyseal tibial 2 mm gap osteotomy model ( Inoue et al, 2002 ).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Fukada and Yusada discovered the piezoelectric property of bone -that bone generates endogenous electrical elds when put under mechanical stress -and its relationship to bone formation in 1953 [2]. Since then, there have been multiple studies in in vitro, small animal, and largeanimal models, as well as clinical studies, to explore the effects of electrical stimulation on an array of osseous injuries [3]. These studies have led to the approval of nine electronic bone growth stimulators (EBGSs) by the Food and Drug Administration (FDA) for use in the treatment of osseous nonunion [4].…”
Section: Introductionmentioning
confidence: 99%